What are the latest developments in new molecular treatments such as mRNA, gene editing, and cell therapy

Today, the 40th JP Morgan Healthcare Conference (JPM) opened online.
A number of biopharmaceutical companies announced the layout, cooperation and progress in the fields of mRNA, gene editing, cell therapy and other new molecular therapeutics
.

Pfizer: Further layout of mRNA technology

Pfizer: Further layout of mRNA technology

Image source: Pfizer official website

Dr.
Albert Bourla, CEO of Pfizer, shared the company's latest progress in the layout of mRNA technology
.

Pfizer believes that mRNA has the potential to bring breakthrough therapies to patients and address unmet medical needs

Today, Pfizer and Beam Therapeutics, a company dedicated to developing base editing technology, have partnered to jointly develop innovative therapeutics based on in vivo base editing for the treatment of rare genetic diseases in the liver, muscle and central nervous system
.

These base editing projects will leverage Beam's in vivo delivery technology to deliver base editing systems to target tissues using lipid nanoparticles (LNPs) and mRNA

At the same time, Pfizer has partnered with Acuitas Therapeutics to utilize Acuitas' LNP delivery technology for up to 10 vaccine or therapeutic R&D projects
.

Acuitas' clinically proven LNP is already being used in a COVID-19 vaccine jointly developed by Pfizer and BioNTech

Today, Pfizer is also partnering with Codex DNA to use its innovative DNA synthesis technology to rapidly and efficiently synthesize complex genes with high fidelity
.

This DNA synthesis technique could cut the time to produce mRNA vaccine candidates in earlier studies from weeks to days

Pfizer said these collaborations will provide a variety of key enabling technologies for the company to further expand mRNA research and development
.

Bayer and Mammoth Biosciences collaborate to develop innovative gene-editing therapies

Bayer and Mammoth Biosciences collaborate to develop innovative gene-editing therapies

Bayer announced a collaboration with Mammoth Biosciences to develop innovative in vivo gene editing therapies using its ultra-small innovative Cas enzymes, including Cas14 and Casɸ
.

Mammoth will receive an upfront payment of $40 million and potential milestone payments of $1 billion

Bristol-Myers Squibb: Deploying Allogeneic Cell Therapy

Bristol-Myers Squibb: Deploying Allogeneic Cell Therapy

Bristol-Myers Squibb (BMS) presented a number of innovative treatments at JPM that will drive future growth, including mavacamten for hypertrophic cardiomyopathy, selective TYK2 inhibitor deucravicitinib, LAG-3 antibody relatlimab, next-generation The anticoagulant drug milvexian, and the molecular glue therapy iberdomide and CC-92480 called CELMoD
.

The company also announced today a $3 billion R&D collaboration with Century Therapeutics to jointly develop allogeneic cell therapies based on the differentiation of induced pluripotent stem cells (iPSCs), including natural killer cell therapy and T cell therapy
.

Moderna partners with Carisma to develop in vivo-generated CAR-M therapy

Moderna partners with Carisma to develop in vivo-generated CAR-M therapy

Moderna today announced an R&D collaboration with Carisma Therapeutics to jointly discover, develop and market in vivo-generated chimeric antigen receptor macrophage (CAR-M) therapies
.

This collaboration will combine Carisma's engineered macrophage technology with Moderna's expertise in mRNA and LNP technologies to directly deliver mRNA encoding chimeric antigen receptors into monocytes and macrophages for the benefit of patients Provides a ready-to-use personalized cell therapy

Allogene: FDA clears all clinical trials of AlloCAR-T therapy

Allogene: FDA clears all clinical trials of AlloCAR-T therapy

Allogene Therapeutics announced today that the FDA has cleared clinical trials of all of the company's AlloCAR-T therapies
.

The FDA previously suspended the company's clinical trials after a chromosomal abnormality was found in a patient treated with the company's investigational allogeneic therapy, ALLO-501A

Further investigation found that the chromosomal abnormality found in this patient was not related to the TALEN gene editing used in the Allogene manufacturing process and was not clinically significant
.

The chromosomal abnormality was also not found in any of the company's AlloCAR-T therapy products, nor in other patients treated with the same batch of ALLO-501A cells

Takeda again deploys γδ T cell therapy

Takeda again deploys γδ T cell therapy

In October of last year, Takeda announced the acquisition of GammaDelta, Inc.
, for a gamma delta T cell therapy platform
.
Today, Takeda once again deployed γδ T cell therapy, announcing the acquisition of Adaptate Biotherapeutics, and the company’s antibody-based γδ T conjugate program
.
These investigational therapies modulate the function of different Vδ1 γδ T cells, and they are designed to allow these binders to specifically modulate γδ T cell-mediated immune responses at the tumor site, while avoiding damage to healthy cells
.